About this trial
In a single-blind, randomised, placebo-controlled crossover manner, this study aims to assess the impact of a high-fat mixed meal containing a whey protein (WP)-enriched milk fat globule membrane (MFGM) powdered ingredient on markers of heart and brain health in the fed state among middle-to-older-aged, postmenopausal women living with overweight and at moderate risk for cardiovascular disease.
Participants will attend two \~8 hour study visits, where they will consume a high-fat meal containing a WP-enriched MFGM powdered ingredient or a placebo WP-based powdered ingredient. Each visit will involve anthropometric measurements and periodic assessments of heart health, including blood pressure and blood vessel stiffness measurements, blood sample collections, as well as computer-based tests measuring mood and cognition (brain function) over a 6-hour postprandial period.
Eligibility criteria
Qualifiers
Apparently healthy postmenopausal women (not menstruating for 12 or more months)
Aged 50 - 75 years
BMI: 25 - 40 kg/m²
Moderate CVD risk
Disqualifiers
Smoking (including vaping)
Diagnosed with cardiovascular disease or suffered myocardial infarction /stroke in the past twelve months
Existing or significant past medical history of any medical condition likely to affect the study outcomes e.g., diabetes, digestive, cancer or thyroidal disease, neurological disease (Alzheimer's disease, other form of dementia, mild cognitive impairment), or serious mental illness know to affect cognition (schizophrenia, schizoaffective disorder, bipolar disorder), learning disorders (dyslexia)
Early or premature menopause resulting from medical conditions or undergoing surgery
Trial design
Treatments tested in this trial
- Whey protein-enriched milk fat globule membrane supplement
- Whey protein-based supplement